Le Lézard
Classified in: Health
Subjects: FDA, PLW

Ortek's Electronic Cavity Detection Device Receives 20th Global Patent


Ortek-ECD® Now Patented in Brazil 

Without Using Radiation, The FDA-Cleared ECD Can Detect Small Cavities Often Missed by X-Rays 

ROSLYN HEIGHTS, N.Y., May 17, 2022 /PRNewswire/ -- Ortek Therapeutics, Inc., a leader in developing and commercializing novel oral care technologies, today announced that the Brazilian Patent and Trademark Office has issued a patent covering the Ortek-ECD®, a revolutionary electronic cavity detection device that can detect tooth decay often missed by X-rays.

With the addition of this newly issued patent in Brazil, the ECD is now covered by 20 issued patents in major global markets with patents now issued in: the United States, Australia, Belgium, Brazil, Canada, China (People's Republic), Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Spain, Sweden and the United Kingdom.

Tooth decay is the world's most common chronic disease and affects an estimated 2.3 billion people worldwide. The majority of cavities occur in the back teeth (molars and premolars). Without using radiation, the ECD painlessly measures the electrical conductance of enamel on these vulnerable sites and can immediately detect the earliest signs of tooth decay that X-rays
often miss. The ECD is cleared by the FDA and is in use by hundreds of dentists in the U.S.

"This is another important milestone for Ortek as we expand the international patent portfolio for the ECD," said Ortek President Mitchell Goldberg. "Early detection of any disease is critically important, and the ECD allows dental professionals to catch tooth decay at a very early stage which helps patients avoid the pain, damage and costs associated with more advanced cavities."

The breakthrough ECD technology was developed and tested at Stony Brook University School of Dental Medicine. Ortek has entered into an exclusive worldwide license to the ECD patents with The Research Foundation for The State University of New York.

About Ortek
Ortek Therapeutics, Inc. is a global leader in developing and commercializing cutting-edge oral care technologies. For more information on the company, visit ortekinc.com.

SOURCE Ortek Therapeutics, Inc.


These press releases may also interest you

at 06:50
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZtm (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis...

at 06:08
The Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland. The Annual General Meeting approved the financial statements for the financial year 1 January?31 December 2023 and resolved to discharge the members of the...

at 06:00
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted...

at 06:00
-- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.26 ---- Increases 2024 Full Year Guidance -- 2024 adjusted diluted EPS of $2.26, up over 7% from $2.11 in the first quarter of 2023.Increases 2024 full year adjusted diluted EPS guidance by $0.10 to...

at 06:00
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first...

at 05:12
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme"). For this purpose, Sobi has prepared a base prospectus, which...



News published on and distributed by: